Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Director Sells 12,116 Shares of Stock

Maplight Therapeutics, Inc. (NASDAQ:MPLT) Director Robert Malenka sold 12,116 shares of the firm’s stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $18.21, for a total transaction of $220,632.36. Following the completion of the transaction, the director owned 339,254 shares of the company’s stock, valued at $6,177,815.34. This trade represents a 3.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Maplight Therapeutics Stock Up 0.3%

NASDAQ MPLT traded up $0.06 on Wednesday, hitting $17.31. The stock had a trading volume of 93,507 shares, compared to its average volume of 188,712. The business has a 50-day moving average of $18.03. Maplight Therapeutics, Inc. has a 52-week low of $12.24 and a 52-week high of $21.55. The company has a market capitalization of $785.35 million and a P/E ratio of -0.47.

Maplight Therapeutics (NASDAQ:MPLT) last released its quarterly earnings results on Thursday, December 4th. The company reported ($37.18) earnings per share for the quarter, missing the consensus estimate of ($1.86) by ($35.32).

Analysts Set New Price Targets

MPLT has been the subject of a number of research analyst reports. Weiss Ratings started coverage on Maplight Therapeutics in a research report on Thursday, January 22nd. They set a “sell (e)” rating for the company. Stifel Nicolaus began coverage on shares of Maplight Therapeutics in a research note on Friday, November 21st. They issued a “buy” rating and a $28.00 price target for the company. Jefferies Financial Group assumed coverage on shares of Maplight Therapeutics in a research report on Friday, November 21st. They set a “buy” rating and a $32.00 price objective on the stock. Wall Street Zen upgraded shares of Maplight Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, December 20th. Finally, Morgan Stanley assumed coverage on Maplight Therapeutics in a research note on Friday, November 21st. They set an “overweight” rating and a $34.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $31.00.

Institutional Trading of Maplight Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Vestal Point Capital LP purchased a new stake in Maplight Therapeutics during the fourth quarter valued at about $6,763,000. Tudor Investment Corp ET AL bought a new stake in shares of Maplight Therapeutics in the 4th quarter valued at about $840,000. Orbimed Advisors LLC purchased a new stake in Maplight Therapeutics during the 4th quarter valued at about $952,000. Oxford Asset Management LLP bought a new position in Maplight Therapeutics during the 4th quarter worth approximately $312,000. Finally, Perceptive Advisors LLC purchased a new position in Maplight Therapeutics in the 4th quarter worth approximately $9,661,000.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.